WO2001032867A1 - Polypeptides possedant des motifs primaires de signalisation etendus - Google Patents

Polypeptides possedant des motifs primaires de signalisation etendus Download PDF

Info

Publication number
WO2001032867A1
WO2001032867A1 PCT/GB2000/004193 GB0004193W WO0132867A1 WO 2001032867 A1 WO2001032867 A1 WO 2001032867A1 GB 0004193 W GB0004193 W GB 0004193W WO 0132867 A1 WO0132867 A1 WO 0132867A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
signalling
acid according
motif
primary
Prior art date
Application number
PCT/GB2000/004193
Other languages
English (en)
Inventor
Helene Margaret Finney
Alastair David Griffiths Lawson
Original Assignee
Celltech R&D Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Limited filed Critical Celltech R&D Limited
Priority to EP00973005A priority Critical patent/EP1226246A1/fr
Priority to JP2001535549A priority patent/JP2003516127A/ja
Priority to AU11562/01A priority patent/AU1156201A/en
Publication of WO2001032867A1 publication Critical patent/WO2001032867A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Definitions

  • the present invention relates to novel cytoplasmic signalling molecules, the nucleic acids that encode them, and the use of such polypeptides and nucleic acids in medicine and research.
  • TCR T cell receptor
  • cellular activation for example, increased cellular proliferation, increased expression of cytokines, stimulation of cytolytic activity, differentiation of other effector functions, antibody secretion, phagocytosis, tumour infiltration and/or increased cellular adhesion, with chimeric receptors has considerable therapeutic potential.
  • chimeric receptors Whilst currently available chimeric receptors are capable of effectively activating cells, there is room for improvement in the efficacy with which the cytoplasmic signalling domain of such a chimeric receptor transduces the signal from the extracellular ligand binding domain to downstream members of the secondary messenger pathway, such as members of the src and syk- tyrosine kinase family.
  • transduction through such a cytoplasmic signalling domain could be improved or manipulated in order to achieve a required level of effector cell activation. It would also be of great benefit if cell activation could be effected with greater efficacy than is possible at present, thus regulating the induction or inhibition of any resultant biological processes.
  • the current invention addresses these difficulties by providing nucleic acids encoding novel cytoplasmic signalling sequences, which, when expressed in effector cells, are capable of efficiently regulating the level of cellular activation.
  • cytoplasmic signalling sequence refers to cytoplasmic sequences of the TCR and co-receptors that act in concert to initiate signal transduction following antigen receptor engagement.
  • the term also encompasses any derivative or variant of these sequences, and any synthetic sequence, that has the same functional capability.
  • Signals generated through the TCR alone are insufficient for full activation of the T cell: a secondary or co-stimulatory signal is also required.
  • cytoplasmic signalling components can be sub-divided into two classes: those that initiate antigen-dependent primary activation through the TCR (primary signalling sequences) and those that act in an antigen-independent manner to provide a secondary or co-stimulatory signal (secondary signalling sequences).
  • the first aspect of this invention provides a nucleic acid encoding a cytoplasmic signalling sequence, which comprises a primary signalling motif that has the consensus amino acid sequence of: Y-X 2 -L/I-X n -Y-X 2 -L/I, wherein amino acid residues are represented by the standard single letter code, X represents any amino acid, a subscripted number indicates the number of residues present at that position within the motif and the value of n is 9 or greater. It is intended that the terms X 2 or X n can represent 2 or n amino acids (respectively) which may either be the same or different. It is also preferred that the value of n lies between 9 and 12, and the value of 9 is especially preferred.
  • primary signalling motif is defined as a sequence that tranduces either a stimulatory or an inhibitory signal, which regulates primary activation of the TCR complex. It will be appreciated that a primary signalling sequence may contain a single motif, or more than one such primary signalling motif.
  • stimulatory, primary signalling motifs conform to the consensus sequence Y-X 2 -L_ / I-X n -Y-X 2 -L/I where the value of n lies between 6 and 8 and is most typically found to be 7. These motifs are also known as immunoreceptor tyrosine-based activation motifs or ITAMs (Isakov, 1998).
  • immunoreceptor tyrosine-based inhibitory motifs comprising the consensus amino acid sequence of l/V-X-Y-X 2 - (Burshtyn et al., 1999) are examples of inhibitory primary signalling motifs. It should be noted that, other than in Figure 2 and in some instances in the examples (where the standard three-letter code is used to describe amino acid sequence), the standard single letter code is used throughout this application to describe both amino acid and nucleotide sequences.
  • the present invention provides novel primary signalling motifs that are capable of modulating the level of primary signal transduction to different degrees and thus provide a range of cellular activation levels. It is known that primary activation involves the binding of src and the syk-family of protein tyrosine kinase to ITAMs and the subsequent phosphorylation of tyrosine residues within the motifs. It is likely therefore, that these novel primary signalling motifs of the invention mediate primary signal transduction through having an altered specificity or affinity for these kinases. This can be analysed quite easily through assay by Western blot using an anti- phosphotyrosine antibody (Sanchez-Garcia, et al., 1997).
  • novel primary signalling motifs of the invention may be employed as the basis of a functional screen for the activity of novel primary signalling motifs of the invention.
  • the consensus sequence of the novel primary signalling motifs differs from that of naturally occurring ITAMs in that distance between the two tyrosine residues is increased by at least one amino acid (i.e. the new motifs conform to a new consensus of Y-X 2 -IJI-X n -Y-X 2 -L_ / I, where the value of n is at least 9).
  • These "expanded" motifs are able to signal at least as well as, if not better than, those with the natural consensus sequence. This is surprising since the corresponding single amino acid decrease in the inter-tyrosine distance (i.e.
  • Primary signalling motifs for use in this invention may be of variable sequence, provided that they conform to the consensus sequence of Y-X ⁇ UI-X n -Y-Xa-L l where the value of n is 9 or greater.
  • preferred motifs are those where the value of n is 9 and particularly preferred motifs are SBX a (which has the amino acid sequence: RKNPQEGLYNELQKDKMAEDTYDALHMQA), SBQ9 a (which has the amino acid sequence: GQNQLYNELQQQQQQQYDVLRRGRDPEM) and SB16 a (which has the amino acid sequence: GQDGLYQELNTRSRDEAAYSVLEGR KAR). Further examples are given in Figure 4 as SBX, SBQ9 and SB16, where GS linkers have additionally been incorporated at each end of the sequence to facilitate cloning.
  • cytoplasmic signalling motifs of the invention when employed as the intracellular domain of a chimeric receptor, the magnitude of a signal transduced through an immune cell receptor may be tailored further by incorporating additional cytoplasmic signalling motifs and/or sequences within the intracellular domain.
  • a nucleic acid is provided that encodes a cytoplasmic signalling molecule comprising a primary signalling motif according to the first aspect of the invention and at least one other primary signalling motif.
  • Primary signalling motifs for use in this aspect of the invention may contain the consensus amino acid sequence Y-X 2 -L/I-X n -Y-X 2 -L/I (single letter code). Where the value of n is 9, SBX a , SBQ9 a or SB16 a , may be employed as the additional motif(s). Where the value of n lies between 6 and 8, it is preferred that the at least one other primary signalling motif will comprise at least part of an immunoreceptor tyrosine based activation motif (ITAM), for example one derived from the TCR ⁇ chain, FcR ⁇ , FcR ⁇ , CD3 ⁇ , CD3 ⁇ , CD3 ⁇ , CD5, CD22, CD79a, CD79b or CD66d.
  • ITAM immunoreceptor tyrosine based activation motif
  • the at the least one other primary signalling motif for use in this aspect of the invention will be derived from all or part of TCR ⁇ l , TCR ⁇ 2, TCR ⁇ 3, FcR ⁇ , FcR ⁇ , CD3 ⁇ , CD3 ⁇ , CD5, CD22, CD79a, CD79b or CD66d.
  • FIG. 1 Source and amino acid sequences of primary signalling motifs of particular use in the invention. The position of the consensus amino acid sequence is emphasised in bold.
  • Figure 4 includes further examples of primary signalling motifs for use in the invention (SB1, SB2, SB3, SB4, SB4 * , SB5, SB6, SB7, SB8, SB9, SB10, SB11, SB12, SB13, SB14, SB15, SB16, SBX and SBQ9), which correspond to the primary signalling motifs shown below with GS linkers incorporated at each end of the motif to facilitate cloning.
  • TCR ⁇ 3 SB3 a RGKGHDGLYQGLSTATKDTYDALHMQA
  • FcR ⁇ SB5 a GNKBPEDRVYEELNIYSATYSELEDPGEMSP
  • CD3 ⁇ SB6 a KQTLLPNDQLYQPLKDREDDQYSHLQGNQLR
  • CD3 ⁇ SB8 a QNKERPPPVPNPDYEPIRKGQRDLYSGLNQRRI
  • CD5 SB9 a HVDNEYSQPPRNSRLSAYPALEGVLHRS
  • CD22 SB10 a PPRTCDDTVTYSALHKRQVGDYENVIPDFPEDE
  • CD66d SB13 a PLPNPRTAASIYEELLKHDTNIYCRMDHKAEVA
  • Non- SB15 a GQDGLYQELNTRSRDEAYSVLEGRKAR natural
  • Non- SB16 a GQDGLYQELNTRSRDEAAYSVLEGRKAR natural
  • Non- SBX a RKNPQEGLYNELQKDKMAEDTYDALHMQA natural
  • Non- SBQ9 a GQNQLYNELQQQQQQQQYDVLRRGRDPEM natural
  • at least one of the additional primary signalling motifs will be non-natural but still conform to the consensus amino acid sequence of sequence Y-X 2 -L/l-X 6 . 8 -Y-X 2 -L/l.
  • non-natural ITAM is meant a synthetic primary signalling motif, the sequence of which has not been found in nature.
  • Preferred examples of such non-natural primary signalling motifs will be SB4 *a , SB14 a or SB15 a as described herein in Table 1 above, or non-natural variants thereof.
  • Preferred combinations of motifs according to this aspect of the invention include multiples of SBQ9 a , SBQX a , or SB16 a ; SBQ9 a , SBX a or SB16 a in combination with each other, or in combination with a primary signalling motif(s) derived from the TCR ⁇ chain (i.e. SB1 a , SB2 a or SB3 a ), or in combination with SB4 *a .
  • the combinations of SB16 a with SB2 a , SB4 *a and SB4 a , and SBX a with SB3 a are particularly preferred.
  • a nucleic acid that encodes a cytoplasmic signalling molecule comprising a primary signalling motif according to the first aspect of the invention and at least one secondary signalling sequence.
  • secondary signalling sequence means a sequence that imparts secondary or co-stimulatory signalling capacity to a molecule in T cells. Molecules containing such sequences include CD2, CD4, CD8, CD28, CD134 and CD154 (see Finney et al., 1998). Preferred secondary signalling sequences for use in the invention are those derived from CD28, CD134 and CD154, for example, SB28 a , which has the amino acid sequence RLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFA, SB29 a , which has the amino acid sequence MIETYNQTSPRSAATGLPISMK and SB34 a , which has the amino acid sequence RRDQRLPPDAHKPPGGGSFRTPIQEEQADAHS TLAKI.
  • Secondary signalling sequences are shown in Figure 4 as SB28, SB29 and SB34, where GS linkers have been incorporated at each end of the sequence to facilitate cloning.
  • Preferred combinations of primary signalling motifs and secondary signalling sequence(s) according to this aspect of the invention include SBQ9 a , SBX a or SB16 a in combination with SB28 a .
  • the combination of SBQ9 a with SB28 a is particularly preferred.
  • Primary signalling motifs may be combined with each other or with secondary signalling sequences in a random or specified order.
  • a glycine- serine doublet provides a particularly suitable linker.
  • Novel cytoplasmic signalling sequences and molecules of the invention can be used either by themselves or as a component part of a larger protein, such as a chimeric receptor.
  • a larger protein such as a chimeric receptor.
  • individual protein molecules they can be introduced into, or expressed in, effector cells in order to act as substitute cytoplasmic signalling sequences for immune cell receptors already expressed within that cell. In this way they can increase the efficiency of signalling through the receptor.
  • they may be introduced into a cell in order to compete with the existing src and syk-protein kinase binding sites and thus, regulate the degree of cell activation by acting as protein kinase inhibitors. Any one of a number of in vitro assays may be used to estimate the efficacy of these novel cytoplasmic signalling molecules as protein tyrosine kinase inhibitors, see for example published International Patent specification W098/11095.
  • cytoplasmic signalling sequences and molecules of this invention are used preferentially to mediate signalling when employed as an intracellular domain of a chimeric receptor protein.
  • chimeric receptors additionally comprise an extracellular ligand-binding domain and a transmembrane domain.
  • an extracellular ligand-binding domain confers on the chimeric receptor the ability to exhibit specificity for a specific ligand or class of ligands.
  • This specificity can be used to define precise ligands or classes of ligands that are capable of activating the receptor. In this way the receptor may be designed to activate the cell in which it is expressed upon binding a chosen class of, or individual, ligand.
  • a further embodiment of the invention thus provides a nucleic acid encoding a chimeric receptor protein that comprises an extracellular ligand-binding domain, a transmembrane domain, and a cytoplasmic signalling domain, wherein the cytoplasmic signalling domain is encoded by a nucleic acid according to any one of the previously described aspects of the invention.
  • extracellular ligand-binding domain is defined as any oligo- or polypeptide that is capable of binding a ligand. Accordingly antibody binding domains, antibody hypervariable loops or CDRs, receptor binding domains and other ligand binding domains, examples of which will be readily apparent to the skilled artisan, are described by this term. Preferably the domain will be capable of interacting with a cell surface molecule.
  • proteins associated with binding to cell surface molecules include, antibody variable domains (V or V ), T-cell receptor variable region domains (TCR , TCR ⁇ , TCR ⁇ , TCR ⁇ ), or the chains of CD8 ⁇ , CD8b, CD11A CD11B, CD11C, CD18, CD29, CD49A, CD49B, CD49D, CD49E, CD49F, CD61 , CD41 , or CD51. Whilst it may be of benefit to use the entire domain or chain in some instances, fragments may be used where appropriate.
  • Particularly useful binding components are derived from antibody binding domains and include Fab 1 fragments and especially single chain Fv fragments.
  • the choice of domain will depend upon the type and number of ligands that define the surface of a target cell.
  • the extracellular ligand binding domain may be chosen to recognise a ligand that acts as a cell surface marker on target cells associated with a particular disease state.
  • cell surface markers that may act as ligands include those associated with viral, bacterial and parasitic infections, autoimmune disease and cancer cells.
  • cell surface markers are the bombesin receptor expressed on lung tumour cells, carcinoembryonic antigen (CEA), polymorphic epithelial mucin (PEM), CD33, the folate receptor, epithelial cell adhesion molecule (EPCAM) and e/t>-B2.
  • CCA carcinoembryonic antigen
  • PEM polymorphic epithelial mucin
  • EPCAM epithelial cell adhesion molecule
  • Other ligands of choice are cell surface adhesion molecules, inflammatory cells present in autoimmune disease, and T-cell receptors or antigens that give rise to autoimmunity.
  • the potential ligands listed above are included by way of example; the list is not intended to be exclusive and further examples will be readily apparent to those of skill in the art.
  • Chimeric receptors may be designed to be bi- or multi-specific i.e. they may comprise more than one ligand binding domain and therefore, be capable of exhibiting specificity for more than one ligand.
  • Such receptors may recruit cellular immune effector cells (e.g. T cells, B cells, natural killer (NK) cells, macrophages, neutrophils, eosinophils, basophils, or mast cells), or components of the complement cascade.
  • T cells e.g. T cells, B cells, natural killer (NK) cells, macrophages, neutrophils, eosinophils, basophils, or mast cells
  • NK natural killer
  • a further component of a chimeric receptor is the transmembrane domain.
  • This may be derived either from a natural or from a synthetic source. Where the source is natural, the domain may be derived from any membrane-bound or transmembrane protein.
  • Transmembrane regions of particular use in this invention may be derived from (i.e. comprise at least the transmembrane region(s) of) the ⁇ , ⁇ or ⁇ chain of the T-cell receptor, CD28, CD3 ⁇ , CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 or CD154.
  • the transmembrane domain is derived from all or part of the ⁇ , ⁇ or ⁇ chain of the T-cell receptor, CD28, CD3 ⁇ , CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64,
  • transmembrane domain derived from CD28 is particularly preferred.
  • the transmembrane domain may be synthetic, in which case it will comprise predominantly hydrophobic residues such as leucine and valine (see for example Published
  • spacer domain generally means any oligo- or polypeptide that functions to link the transmembrane domain to, either the extracellular ligand-binding domain or, the cytoplasmic signalling domain in the polypeptide chain.
  • a spacer domain may comprise up to 300 amino acids, preferably 10 to 100 amino acids and most preferably 25 to 50 amino acids.
  • Spacer domains may be derived from all or part of naturally occurring molecules, such as from all or part of the extracellular region of CD8, CD4, or CD28; all or part of an antibody constant region; all or part of natural spacer components between functional parts of cytoplasmic signalling components, for example spacers between ITAMs.
  • the spacer may be an entirely synthetic spacer sequence.
  • Spacer domains may be designed in such a way that they, either minimise the constitutive association of chimeric receptors, thus reducing the incidence of constitutive activation in the cell or, promote such associations and enhance the level of constitutive activation in the cell. Either possibility may be achieved artificially by deleting, inserting, altering or otherwise modifying amino acids and naturally occurring sequences in the transmembrane and/or spacer domains, which have side chain residues that are capable of covalently or non-covalently interacting with the side chains of amino acids in other polypeptide chains.
  • Particular examples of amino acids that can normally be predicted to promote association include cysteine residues, charged amino acids or amino acids such as serine or threonine within potential glycosylation sites.
  • cytoplasmic signalling molecules of the invention may be linked to other intracellular components, or to the transmembrane domain through a short oligo- or polypeptide linker, preferably between 2 and 10 amino acids.
  • a glycine-serine doublet provides a particularly suitable linker.
  • Chimeric receptors may be designed in such a way that the spacer and transmembrane components have free thiol groups, thereby providing the receptor with multimerisation, and particularly dimerisation, capacity. Such multimeric receptors are preferred, especially dimers. Receptors with transmembrane and spacer domains derived from CD28 components, the zeta chain of the natural T cell receptor, and/or antibody hinge sequences are especially preferred.
  • cytoplasmic signalling motif/molecule of the invention When a cytoplasmic signalling motif/molecule of the invention is employed as the intracellular domain of a chimeric receptor, this activation/inhibition may be initiated though a single binding event at the extracellular ligand-binding domain. It will be clear to the skilled technician that combinations of cytoplasmic signalling motifs, or motifs and sequences, can be on separate polypeptide chains or may be in series on a single polypeptide chain. This concept of either a single polypeptide chain, or multiple polypeptide chains, providing the comprising elements, is equally applicable to the chimeric receptors of the present invention.
  • the current invention also provides novel cytoplasmic signalling proteins and chimeric receptor proteins encoded by a nucleic acid as described in any of the previously described aspects of the invention.
  • Nucleic acid coding sequences for the novel primary signalling motifs, for use in this invention are readily derived from the specified amino acid sequences. Other nucleic acid sequences are widely reported in the scientific literature and are also available in public databases. DNA may be commercially available, may be part of cDNA libraries, or may be generated using standard molecular biology and/or chemistry procedures as will be clear to those of skill in the art.
  • Particularly suitable techniques include the polymerase chain reaction (PCR), oligonucleotide-directed mutagenesis, oligonucleotide-directed synthesis techniques, enzymatic cleavage or enzymatic filling-in of gapped oligonucleotide.
  • PCR polymerase chain reaction
  • oligonucleotide-directed mutagenesis oligonucleotide-directed synthesis techniques
  • enzymatic cleavage or enzymatic filling-in of gapped oligonucleotide are described by Sambrook & Fritsch, 1989, and in the Examples contained hereinafter.
  • the nucleic acids of the invention may be used with a carrier.
  • the carrier may be a vector or other carrier suitable for the introduction of the nucleic acids ex-vivo or in-vivo into target cell and/or target host cells.
  • suitable vectors include viral vectors such as retroviruses, adenoviruses, adeno-associated viruses (AAVs), Epstein-Barr virus (EBV) and Herpes simplex virus (HSV).
  • Non-viral vector may also be used, such as liposomal vectors and vectors based on condensing agents such as the cationic lipids described in International patent application numbers WO96/10038, W097/18185, W097/25329, WO97/30170 and W097/31934.
  • the vector may additionally include promoter and regulatory sequences and/or replication functions from viruses, such as retrovirus long terminal repeats (LTRs), AAV repeats, SV40 and human cytomegalovirus (hCMV) promoters and/or enhancers, splicing and polyadenylation signals and EBV and BK virus replication functions.
  • viruses such as retrovirus long terminal repeats (LTRs), AAV repeats, SV40 and human cytomegalovirus (hCMV) promoters and/or enhancers, splicing and polyadenylation signals and EBV and BK virus replication functions.
  • TTRs retrovirus long terminal repeats
  • AAV repeats SV40 and human cytomegalovirus (hCMV) promoters and/or enhancers
  • splicing and polyadenylation signals and EBV and BK virus replication functions.
  • TCR- ⁇ promoter such as the TCR- ⁇ promoter, E-selectin promoter and the CD2 promoter and locus control region
  • the invention also includes cloning and expression vectors containing a nucleic acid according to any of the above-described aspects of the invention.
  • Such expression vectors will incorporate the appropriate transcriptional and translation control sequences, for example, enhancer elements, promoter-operator regions, termination stop sequence, mRNA stability sequences, start and stop codons or ribosome binding sites, linked where appropriate in-frame with the nucleic acid molecules of the invention.
  • nucleic acid sequences encoding secretion signalling and processing sequences may include nucleic acid sequences encoding secretion signalling and processing sequences.
  • Vectors according to the invention include plasmids and viruses (including both bacteriophage and eukaryotic viruses).
  • Many expression systems suitable for the expression of heterologous proteins are well known and documented in the art.
  • prokaryotic cells such as Escherichia coli to express heterologous polypeptides and polypeptide fragments is well established (see for example, Sambrook & Fritsch, 1989, Glover, 1995a).
  • eukaryotic expression systems have been well developed and are commonly used for heterologous protein expression (see for example, Glover, 1995b and O'Reilly et al., 1993).
  • the vectors of choice are virus-based.
  • Particularly suitable viral vectors include baculovirus-, adenovirus-, and vaccinia virus-based vectors.
  • Vectors containing the relevant regulatory sequences can either be chosen from those documented in the literature, or readily constructed for the expression of the proteins of this invention using standard molecular biology techniques. Such techniques, and protocols for the manipulation of nucleic acids, for example in the preparation of nucleic acid constructs, mutagenesis, sequencing, DNA transformation and gene expression, as well as the analysis of proteins, are described in detail in Ausubel er a/., 1992 or Rees et al., 1993. Suitable host cells for the in vitro expression of high levels of cytoplasmic signalling molecules or chimeric receptors include prokaryotic cells e.g. E.
  • coli eukaryotic yeasts e.g Saccharomyces cerevisiae, Pichia species, Schizosaccharomyces pombe, mammalian cell lines and insect cells.
  • recombinant proteins or chimeric receptors may be expressed in vivo, for example in insect larvae, or plant cells or more preferably in mammalian tissues.
  • Nucleic acid may be introduced into a host cell by any suitable technique.
  • these techniques may include calcium phosphate transfection, DEAE-Dextran, electroporation, particle bombardment, liposome-mediated transfection or transduction using retrovirus, adenovirus or other viruses, such as vaccinia or, for insect cells, baculovirus.
  • suitable techniques may include calcium chloride transformation, electroporation or transfection using bacteriophage.
  • the nucleic acid may remain in an episomal form within the cell, or it may integrate into the genome of the cell. If the latter is desired, sequences that promote recombination with the genome will be included in the nucleic acid.
  • the cells may be cultured under conditions to enhance or induce expression of the recombinant cytoplasmic signalling molecule or chimeric receptor protein as appropriate.
  • nucleic acid encoding a cytoplasmic signalling protein and/or chimeric receptor protein of the invention, and host cells expressing such proteins.
  • nucleic acids of the invention be employed in either ex-vivo or in-vivo therapies.
  • the nucleic acid may be introduced into effector cells, removed from the target host, using methods well known in the art e.g. transfection, transduction (including viral transduction), biolistics, protoplast fusion, calcium phosphate mediated DNA transformation, electroporation, cationic lipofection, or targeted liposomes.
  • the effector cells are then reintroduced into the host using standard techniques.
  • suitable effector cells for the expression of the chimeric receptors of the present invention include cells associated with the immune system such as lymphocytes e.g.
  • cytotoxic T-lymphocytes tumour infiltrating lymphocytes, neutrophils, basophils, or T-helper cells, dendritic cells, B-cells, haematopoietic stem cells, macrophages, monocytes or NK cells.
  • the use of cytotoxic T-lymphocytes is especially preferred.
  • the nucleic acid according to this aspect of the invention is particularly suitable for in vivo administration.
  • the DNA may be in the form of a targeted carrier system in which a carrier as described above is capable of directing DNA to a desired effector cell.
  • suitable targeted delivery systems include targeted naked DNA, targeted liposomes encapsulating and/ or complexed with the DNA, targeted retroviral systems and targeted condensed DNA such as protamine and polylysine-condensed DNA.
  • Targeting systems include, for example, using antibodies or fragments thereof against cell surface antigens expressed on target cells in vivo such as CD8, CD16, CD4, CD3, selecting (e.g. E-selectin), CD5, CD7, CD24, and activation antigens (e.g. CD69 and IL-2R.
  • CD8 e.g. CD8
  • CD16 e.g. CD16
  • CD4 e.g. CD5
  • CD7 e.g. CD24
  • activation antigens e.g. CD69 and IL-2R.
  • other receptor-ligand interactions can be used for targeting e.g. CD4 to target HIV gp 160-expressing target cells.
  • antibody-targeted DNA is preferred, particularly antibody-targeted naked DNA, antibody-targeted condensed DNA and especially antibody-targeted liposomes.
  • Types of liposomes that may be used include for example pH-sensitive liposomes, where linkers that are cleaved at low pH may be used to link the antibody to the liposome.
  • the nucleic acids of the present invention may also be targeted directly to the cytoplasm by using cationic liposomes, which fuse with the cell membrane.
  • Liposomes for use in the invention may also have hydrophilic molecules, e.g. polyethylene glycol polymers, attached to their surface to increase their circulating half-life.
  • the antibody or other targetting molecule may be linked to the DNA, condensed DNA or liposome using conventional linking groups and reactive functional groups in the antibody, e.g. thiols or amines, and in the DNA or DNA-containing material.
  • Non-targeted carrier systems may also be used.
  • targeted expression of the protein is advantageous. This may be achieved, for example, by using T cell specific promoter systems such as the zeta promoter, CD2 promoter and locus control region, CD4, CD8 TCR and TCR ⁇ promoters, cytokine promoters, such as the IL2 promoter, and the perforin promoter.
  • T cell specific promoter systems such as the zeta promoter, CD2 promoter and locus control region, CD4, CD8 TCR and TCR ⁇ promoters, cytokine promoters, such as the IL2 promoter, and the perforin promoter.
  • cytoplasmic signalling proteins and/or chimeric receptor proteins of the present invention be applied in methods of therapy of mammalian, particularly human, patients.
  • Signalling molecules and chimeric receptor proteins generated by the present invention may be particularly useful in the treatment of a number of diseases or disorders.
  • diseases or disorders may include those described under the general headings of infectious diseases, e.g. HIV infection; inflammatory disease/autoimmunity e.g. asthma, eczema; congenital e.g. cystic fibrosis, sickle cell anaemia; dermatologic, e.g. psoriasis; neurologic, e.g. multiple sclerosis; transplants e.g. organ transplant rejection, graft-versus-host disease; metabolic/idiopathic disease, e.g. diabetes; cancer.
  • infectious diseases e.g. HIV infection
  • inflammatory disease/autoimmunity e.g. asthma, eczema
  • expression of a chimeric receptor on the surface of a T cell may initiate the activation of that cell upon binding of the ligand-binding domain to a ligand on a target cell.
  • the ensuing release of inflammatory mediators stimulated by the activation of the signalling function of the receptor ensures destruction of the target cell.
  • a chimeric receptor according to the present invention is expressed in an effector cell of the immune system, binding to target will activate the effector cell; downstream effects of this activation may also result in the destruction of the target cell.
  • the extracellular ligand-binding domain of the chimeric receptor exhibits specificity for a surface marker on an immune cell, effector cells may be recruited to the site of disease. Accordingly, expression of a chimeric receptor in a diseased cell will ensure its destruction.
  • multispecific chimeric receptor proteins or more than one chimeric receptor (with different ligand specificities), within a single host cell, may confer dual functionality on the receptor. For example, binding of the chimeric receptor to its target may not only activate the effector cell itself, but may additionally attract other immune effectors to the site of disease. The target cell may thus be destroyed by the activation of the immune system.
  • a further aspect of the invention provides a composition comprising a cytoplasmic signalling protein and/or chimeric receptor protein of the invention, or nucleic acid(s) encoding such a protein, in conjunction with a pharmaceutically acceptable excipient.
  • Suitable excipients will be well known to those of skill in the art and may, for example, comprise a phosphate-buffered saline (e.g. 0.01 M phosphate salts, 0.138M NaCI, 0.0027M KCI, pH7.4), a liquid such as water, saline, glycerol or ethanol, optionally also containing mineral acid salts such as hydrochlorides, hyd rob rom ides, phosphates, sulphates and the like; and the salts of organic acids such as acetates propionates, malonates, benzoates and the like.
  • mineral acid salts such as hydrochlorides, hyd rob rom ides, phosphates, sulphates and the like
  • the salts of organic acids such as acetates propionates, malonates, benzoates and the like.
  • Auxiliary substances such as wetting or emulsifying agents, and pH buffering substances, may also be present
  • compositions will be in a form suitable for parenteral administration e.g. by injection or infusion, for example by bolus injection or continuous infusion or particle-mediated injection.
  • parenteral administration e.g. by injection or infusion
  • it may take the form of a suspension, solution or emulsion in an oily or aqueous vehicle and it may contain formulatory agents such as suspending, preservative, stabilising and/or dispersing agents.
  • the composition may be in dry form, for reconstitution before use with an appropriate sterile liquid.
  • DNA may be coated on particles such as microscopic gold particles.
  • a carrier may also be used that does not itself induce the production of antibodies harmful to the individual receiving the composition and which may be administered without undue toxicity.
  • Suitable carriers are typically large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and inactive virus particles.
  • Pharmaceutical compositions may also contain preservatives in order to prolong shelf life in storage.
  • the formulation may contain, in addition to the active ingredient additives such as starch (e.g. potato, maize or wheat starch, cellulose), starch derivatives such as microcrystalline cellulose, silica, various sugars such as lactose, magnesium carbonate and/or calcium phosphate.
  • active ingredient additives such as starch (e.g. potato, maize or wheat starch, cellulose), starch derivatives such as microcrystalline cellulose, silica, various sugars such as lactose, magnesium carbonate and/or calcium phosphate.
  • mucus formers and resins it may also be desirable to improve tolerance by formulating the compositions in a capsule that is insoluble in the gastric juices.
  • novel cytoplasmic signalling proteins or chimeric receptor proteins, or the nucleic acids encoding such proteins, or of a pharmaceutical composition in the manufacture of a medicament for the treatment or prevention of disease in humans or in animals is also provided.
  • FIGURES Figure 1 Schematic representation of the cloning cassette used in the construction of chimeric receptors with novel signalling components.
  • Figure 2 Nucleotide and amino acid sequence of h.CD28 extracellular spacer and the human CD28 transmembrane region used in the construction of the cloning cassette describe in Figure 1.
  • Figure 3 Oligonucleotide sequences used in the construction of chimeric receptors.
  • Figure 4 Amino acid sequences of primary and secondary signalling sequences employed in the construction of chimeric receptors.
  • Figure 5 Antigen specific stimulation of chimeric receptors with primary signalling motifs that vary in their inter-tyrosine distance.
  • Figure 6 Antigen specific stimulation of a chimeric receptor with an expanded primary signalling motif in conjunction with an addition primary signalling motif.
  • Figure 7 Antigen specific stimulation of chimeric receptors that comprise primary signalling motifs, which vary in their inter-tyrosine distance, in conjunction with a secondary signalling sequence.
  • the binding component has 5' (relative to coding direction) Not I and Hind III restriction sites and a 3' (again relative to coding direction) Spe I restriction site.
  • the extracellular spacer is flanked by a Spe I site (therefore encoding Thr, Ser at the 5' end) and a Nar I site (therefore encoding Gly, Ala at the 3' end).
  • the transmembrane component is flanked by a Nar I site at its 5' end (therefore encoding Gly, Ala) and by Mlu I (therefore encoding Thr, Arg) and BamH I sites (therefore encoding Gly, Ser) at the 3' end.
  • the signalling component may be cloned in-frame into the BamH I site. Following this BamH I site there is a stop codon for transcription termination and there is also an EcoR I site situated downstream of this to facilitate the subsequent rescue of whole constructs.
  • a 200bp fragment was assembled by PCR, using the following oligos; S0146, A6081 , A6082 and A6083 ( Figure 3).
  • the nucleotide and amino acid sequences of this fragment are shown in Figure 2. It starts with a Spel site and consists of the extracellular spacer h.CD28, the human CD28 transmembrane region, a stop codon and finishes with an EcoR I restriction site.
  • This PCR fragment was then digested with Spe I and EcoR I and substituted for the same fragment in our previously described cloning cassette system ( Figure 2 of published International Patent application WO 97/23613) in order to clone it in-frame with the binding component.
  • Example 2 The construction of sequence blocks of primary and secondary signalling motifs
  • Each sequence block (SB) was generated by annealing two oligos such that they had single-stranded overhangs forming half a Bel I site at the 5' end and half a BamH I site at the 3' end. Oligos were annealed at a concentration of 1 pmol ⁇ / ⁇ l in buffer (25mM NaCI, 12.5 mM Tris-HCI, 2.5mM MgCI 2 , 0.25mM DTE, pH 7.5) by heating in a boiling water bath for 5 minutes and then allowing them to cool slowly to room temperature.
  • buffer 25mM NaCI, 12.5 mM Tris-HCI, 2.5mM MgCI 2 , 0.25mM DTE, pH 7.5
  • SB1 This sequence is based on the first ITAM of human TCR ⁇ and was constructed by annealing oligos A8816 and A8817.
  • SB2 This sequence is based on the second ITAM of human TCR ⁇ and was constructed by annealing oligos A8814 and A8815.
  • SB3 This sequence is based on the third ITAM of human TCR ⁇ and was constructed by annealing oligos A8812 and A8813.
  • SB4 This sequence is based on the ITAM of the ⁇ chain of human Fc ⁇ R1 and was constructed by annealing oligos A8810 and A8811.
  • SB5 This sequence is based on the ITAM of the ⁇ chain of human
  • Fc ⁇ R1 was constructed by annealing oligos A9000 and A9001.
  • g) SB6 This sequence is based on the ITAM of the ⁇ chain of human CD3 and was constructed by annealing oligos A9002 and A9003.
  • SB7 This sequence is based on the ITAM of the ⁇ chain of human CD3 and was constructed by annealing oligos A9004 and A9005.
  • SB8 This sequence is based on the ITAM of the ⁇ chain of human CD3 and was constructed by annealing oligos A9006 and A9007.
  • SB9 This sequence is based on the ITAM of human CD5 and was constructed by annealing oligos A9008 and A9009.
  • SB10 This sequence is based on the ITAM of human CD22 and was constructed by annealing oligos A9010 and A9011.
  • SB11 This sequence is based on the ITAM of human CD79a and was constructed by annealing oligos A9012 and A9013.
  • m) SB12 This sequence is based on the ITAM of human CD79b and was constructed by annealing oligos A9014 and A9015.
  • n) SB13 This sequence is based on the ITAM of human CD66d and was constructed by annealing oligos A9016 and A9017.
  • SB14 This sequence is synthetic and was constructed by annealing oligos D5258 and D5259.
  • p) SB15 This sequence is synthetic and was constructed by annealing oligos F6392 and F6394.
  • SB28 This sequence is based on the secondary signalling (costimulation) sequence of human CD28 and was constructed by annealing oligos A9018 and A9019.
  • SB29 This sequence is based on the secondary signalling (costimulation) sequence of human CD154 and was constructed by annealing oligos A9020 and A9021.
  • t) SB34 This sequence is based on the secondary signalling (costimulation) sequence of human CD134 and was constructed by annealing oligos F1340A and F1340B.
  • SBQ5 This sequence is synthetic and was constructed by annealing oligos D7609 and D7610.
  • SBQ7 This sequence is synthetic and was constructed by annealing oligos D7613 and D7614.
  • SBQ9 This sequence is synthetic and was constructed by annealing oligos D7617 and D7618.
  • SBX This sequence resulted from a recombination event between SB2 and SB3 during cloning.
  • Example 3 The construction of receptors with different signalling components.
  • This cassette also facilitates exchange of binding components on a Not I or Hind III to Spe I fragment as well as the exchange of extracellular spacers on a Spe I to Nar I fragment and the exchange of the transmembrane region on a Nar I to Mlu I fragment.
  • chimeric receptors with different binding, extracellular spacer, transmembrane and signalling components can be assembled readily.
  • Example 4 Analysis of chimeric receptors a) Construction of expression plasmids. The chimeric receptor constructs were sub-cloned from pBluescript KS+ into the expression vector pEE6hCMV.ne (Cockett, et al, 1991 ) on a Hind III to EcoR I restriction fragment. The empty expression vector (i.e the base vector lacking in chimeric receptor genes) is used as a negative control.
  • the expression plasmids were transfected using DuoFect (Quantum Biotechnologies Inc.) according to the manufacturer's instructions.
  • FITC-labelled CD33 antigen was employed for analysis of receptors with a P67scFV binding component. Fluorescence was analysed by a FACScan cytometer (Becton Dickinson).
  • IL-2 production 2X10 5 cells were incubated at 37°C in 8% C0 2 for 20 hours in 96 well plates with target cells at an effecto ⁇ target ratio of 1 :1. Cell supematants were then harvested and assayed for human IL-2 (R & D Systems Quantikine kit).
  • HL60 cells - a human cell line naturally expressing the antigen, CD33.
  • N.EE6 - a mouse myeloma (NSO) transfected with a control expression vector. These cells are used as a negative control target cell line.
  • N.CD33 - a mouse myeloma (NSO) transfected with an expression vector facilitating the expression of antigen CD33 on the cell surface.
  • IL-2 The specific production of IL-2 by Jurkat cells expressing chimeric receptors, in response to antigen challenge (either by HL-60 or N.CD33 cells as indicated), is used as a measure of signalling capability and the degree of cellular activation in all of the experiments described below.
  • N.CD33 cells were used to provide an antigen challenge to Jurkat cells expressing chimeric receptors with primary signalling motifs that vary in their inter-tyrosine distance.
  • the results demonstrate that chimeric receptors with primary signalling motifs that have a longer (9 amino acid) spacer between YXXL motifs, as in SB16, are better at signalling than those with an average natural distance (7 amino acids) as in SB14.
  • HL60 cells were used to provide an antigen challenge to Jurkat cells expressing a chimeric receptor with an expanded primary signalling motif.
  • the results, illustrated in Figure 6, show the extremely efficient production of IL-2 by cells expressing such novel chimeric receptors.
  • the primary signalling motif SB3 a has been included upstream of the expanded motif SBX a , to generate the highly efficient receptor P67scFV/h.CD28/CD28tm/SB3.SBX.
  • chimeric receptors comprising the novel primary signalling motifs, SBQ5 a , SBQ7 a and SBQ9 a , as well as the secondary signalling sequence SB28 a , were challenged with N.CD33 cells. All chimeric receptors are capable of signalling however, a longer (9 amino acids), rather than shorter (5 amino acids), spacer between YXXL motifs in the primary signalling motifs again shown to be more efficacious than a spacer of average natural length (7 amino acids).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)

Abstract

L'invention concerne de nouveaux motifs primaires de signalisation contenant la séquence aminoacide de consensus de Y-X2-L/I-Xn-Y-X2-L/I, dans laquelle n est égal ou supérieur à 9. Ces nouveaux motifs sont extrêmement efficaces pour la transduction de signaux de cellules immunes, en particulier, quand ils sont incorporés dans un domaine de signalisation intracellulaire d'un récepteur chimère. Elle concerne également des acides nucléiques codant ces motifs primaires de signalisation stimulateurs et artificiels, pouvant être mis en application en médecine, ainsi que les polypeptides les contenant.
PCT/GB2000/004193 1999-11-01 2000-11-01 Polypeptides possedant des motifs primaires de signalisation etendus WO2001032867A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00973005A EP1226246A1 (fr) 1999-11-01 2000-11-01 Polypeptides possedant des motifs primaires de signalisation etendus
JP2001535549A JP2003516127A (ja) 1999-11-01 2000-11-01 延長第一シグナル伝達モチーフを有するポリペプチド
AU11562/01A AU1156201A (en) 1999-11-01 2000-11-01 Polypeptides with expanded primary signalling motifs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9925853.5 1999-11-01
GBGB9925853.5A GB9925853D0 (en) 1999-11-01 1999-11-01 Biological products

Publications (1)

Publication Number Publication Date
WO2001032867A1 true WO2001032867A1 (fr) 2001-05-10

Family

ID=10863768

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/004193 WO2001032867A1 (fr) 1999-11-01 2000-11-01 Polypeptides possedant des motifs primaires de signalisation etendus

Country Status (5)

Country Link
EP (1) EP1226246A1 (fr)
JP (1) JP2003516127A (fr)
AU (1) AU1156201A (fr)
GB (1) GB9925853D0 (fr)
WO (1) WO2001032867A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003011898A2 (fr) * 2001-07-27 2003-02-13 Institut Pasteur Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
EP3009448A1 (fr) 2006-07-25 2016-04-20 UCB Biopharma SPRL Polypeptides fc à chaîne simple

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997023613A2 (fr) * 1995-12-21 1997-07-03 Celltech Therapeutics Ltd. Procede d'activation de cellules et ses reactifs
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925854D0 (en) * 1999-11-01 1999-12-29 Celltech Therapeutics Ltd Biological products

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
WO1997023613A2 (fr) * 1995-12-21 1997-07-03 Celltech Therapeutics Ltd. Procede d'activation de cellules et ses reactifs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 15 October 1998 (1998-10-15), ENDO K ET AL.: "Homo sapiens signal transducing adaptor molecule 2A (STAM2) mRNA, complete cds.", XP002162129 *
MEYAARD L ET AL: "LAIR-1, A NOVEL INHIBITORY RECEPTOR EXPRESSED ON HUMAN MONONUCLEAR LEUKOCYTES", IMMUNITY,US,CELL PRESS, vol. 7, no. 2, 1 August 1997 (1997-08-01), pages 283 - 290, XP002061091, ISSN: 1074-7613 *
See also references of EP1226246A1 *
TAKESHITA TOSHIKAZU ET AL: "Cloning of a novel signal-transducing adaptor molecule containing an SH3 domain and ITAM.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 225, no. 3, 1996, pages 1035 - 1039, XP002162128, ISSN: 0006-291X *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003011898A2 (fr) * 2001-07-27 2003-02-13 Institut Pasteur Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
WO2003011898A3 (fr) * 2001-07-27 2005-03-17 Pasteur Institut Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
CN1630663B (zh) * 2001-07-27 2010-05-12 巴斯德研究所 结合蛋白磷酸酶2a的合成的或者天然的肽,其鉴定方法以及用途
US8299213B2 (en) 2001-07-27 2012-10-30 Universite Pierre Et Marie Curie (Paris 6) Synthetic or natural peptides binding protein phosphatase 2A, identification method and uses
EP3009448A1 (fr) 2006-07-25 2016-04-20 UCB Biopharma SPRL Polypeptides fc à chaîne simple

Also Published As

Publication number Publication date
AU1156201A (en) 2001-05-14
EP1226246A1 (fr) 2002-07-31
GB9925853D0 (en) 1999-12-29
JP2003516127A (ja) 2003-05-13

Similar Documents

Publication Publication Date Title
EP1226244B1 (fr) Polypeptides a motifs de signalisation primaire non naturelle
US20040038886A1 (en) Chimeric cytoplasmic signalling molecules derived from cd137
AU768761B2 (en) Chimeric receptors
US7052906B1 (en) Synthetic transmembrane components
US20060247191A1 (en) Chimeric cytoplasmic signalling molecules
AU729757B2 (en) Cell activation process and reagents therefor
CA2429384C (fr) Immunoadhesion concatamerique
EP1543032B1 (fr) Procede de mutagenese rationnelle de recepteurs de lymphocytes t a/beta et recepteurs de lymphocytes t a/beta specifiques de la proteine mdm2 ayant subi ladite mutagenese rationnelle
EP1847608B1 (fr) Membre de la famille des ligands du TNF
JP2002511757A (ja) 細胞活性化プロセスおよびそのための試薬
WO2000063372A1 (fr) Molecules de signalisation synthetiques
DE10259713A1 (de) Verfahren zur Expressionsstabilisierung und Verbesserung der spezifischen Effektorfunktion von Einzelketten-Antigenerkennenden genetischen Konstrukten (scARC) und entsprechend mutierten MDM2-Protein spezifischen scT-Zell Rezeptoren
EP1226246A1 (fr) Polypeptides possedant des motifs primaires de signalisation etendus
WO2001032866A2 (fr) Recepteurs-adaptateurs
KR20220020229A (ko) Il-12 및 항-cd20 항체를 포함하는 융합단백질 및 이의 용도
KR102014400B1 (ko) Ceacam6에 특이적으로 결합하는 항-ceacam6 키메릭 항원 수용체
EP1171592A1 (fr) Methode destinee a modifier les proprietes d'une proteine associee a une membrane par substitution du domaine transmembranaire

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 535549

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000973005

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000973005

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000973005

Country of ref document: EP